Autolus Therapeutics plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 6A3A.F | ALLO | CABA | FATE | RNAC | PGEN | |
|---|---|---|---|---|---|---|
| Market cap | 391.26M | 459.50M | 272.97M | 246.83M | 193.48M | 2.45B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.8 | -2.2 | -1.4 | -2.1 | -1.7 | -31.0 |
| Price/book | 5.9 | 1.1 | 1.3 | 1.6 | -1.5 | 56.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −3.47% | +9.92% | −34.29% | +38.26% | −28.87% | +74.68% |
| Today | +4.26% | +2.31% | +8.78% | +10.75% | +5.18% | +2.55% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 6A3A.F news ›Autolus Therapeutics (AUTL) Receives a Buy from Wells Fargo
In a report released on October 2, from Wells Fargo maintained a Buy rating on Autolus Therapeutics, with a price target of $5.00. The company’... In a report released on October 2, from Wells Fargo maintained a Buy rating on Autolus…
Autolus Therapeutics management to meet virtually with William Blair
Virtual Meeting to be held on September 24 hosted by William Blair. Published first on TheFly – the ultimate source for real-time, market-movin... Autolus Therapeutics management to meet virtually with William Blair Virtual Meeting to be…
H.C. Wainwright Keeps Their Buy Rating on Autolus Therapeutics (AUTL)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Autolus Therapeutics, with a price target of $10.00. According to TipRanks, Bodnar is a 4-star analyst with an average return of 4.1% and a 37.75%…
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Abstract : 2216Title : Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com3
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.